Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

MYNZ Mainz BioMed NV

0,304

-0,0164 (-5,12%)

14 Sep 2024 - Geschlossen

Verzögert um 15 Minuten

Micro Cap Bid Up Following FDA Submission Announcement

A medical company based out of Germany is already turning heads during Tuesday’s premarket hours after the company announced the submission of its application to the U.S....

To read the full story on AllPennyStocks.com, click here.

Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
Von Aug 2024 bis Sep 2024

Click Here for more Mainz BioMed NV Charts.

Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
Von Sep 2023 bis Sep 2024

Click Here for more Mainz BioMed NV Charts.

News Mainz BioMed NV

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Mittwoch 4 September 2024 (1 Woche vor) • GlobeNewswire Inc.

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Donnerstag 25 Juli 2024 (2 Monate vor) • GlobeNewswire Inc.

Micro Cap Bid Up Following FDA Submission Announcement
Dienstag 9 Juli 2024 (2 Monate vor) • AllPennyStocks.com

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Dienstag 9 Juli 2024 (2 Monate vor) • GlobeNewswire Inc.

Mainz Biomed Provides Half Year 2024 Corporate Update
Dienstag 2 Juli 2024 (2 Monate vor) • GlobeNewswire Inc.

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Montag 3 Juni 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Freitag 31 Mai 2024 (3 Monate vor) • Edgar (US Regulatory)

Mainz Biomed Reports Results of 2024 Annual General Meeting
Freitag 31 Mai 2024 (3 Monate vor) • GlobeNewswire Inc.

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Dienstag 28 Mai 2024 (4 Monate vor) • GlobeNewswire Inc.

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
Montag 20 Mai 2024 (4 Monate vor) • GlobeNewswire Inc.

Form D/A - Notice of Exempt Offering of Securities: [Amend]
Freitag 10 Mai 2024 (4 Monate vor) • Edgar (US Regulatory)

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Dienstag 7 Mai 2024 (4 Monate vor) • GlobeNewswire Inc.

Weitere Mainz BioMed NV News-Artikel

Deutsche Telekom

Health Care Select Sector

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen